The Senate may not consider the FDA Reauthorization Act (FDARA) until early September, after the congressional recess. The delay comes after Senator John McCain (R-Arizona) returned to the capitol to vote in favor of advancing a debate over healthcare reform.
While many expected the FDA Reauthorization Act of 2017 (FDARA) to move more swiftly through the Senate after the Better Care Reconciliation Act failed to garner enough votes to pass the chamber, Inside Health Policy reports that the Senate may not consider the FDARA until early September, after the congressional recess. The delay comes after Senator John McCain (R-Arizona) returned to the capitol to vote in favor of advancing a debate over healthcare reform—a debate that left the Senate little room to debate any other proposed legislation.
The bipartisan FDARA, which would reauthorize user fees for biosimilar product applications, among other provisions, was passed by a voice vote in the House earlier this month. To ensure funding for the continued operations of the FDA, the Senate must pass the bill by the end of September.
Debate over the bill is likely to include the consideration of amendments that dominated committee meetings, including Senator Bernie Sanders’ (I-Vermont) drug importation amendment that would allow the importation of cheaper drugs from Canada. Sanders voted against advancing the FDARA out of committee after his proposed amendment was tabled.
The Senate is also likely to debate Senato Ron Johnson's (R-Wisconsin) “right to try” legislation, which would allow patients who have terminal illnesses to try as-yet unapproved experimental treatments. Johnson has declared that he will attempt to prevent the bill from passing unless it includes his proposed amendment.
According to Inside Health Policy, the debate could also focus on the cosmetics bill floated by Senators Dianne Feinstein (D-California) and Susan Collins (R-Maine), which would grant the FDA the authority to issue recalls on cosmetic products, as well as Senator Johnny Isakson’s (R-Georgia) over-the-counter monograph bill that would provide a user fee program and potential 2-year exclusivity for over-the-counter drugs.
While the Biosimilar User Fee Act will expire at the end of September, FDA Commissioner Scott Gottlieb, MD, has indicated that he will delay any layoffs of FDA staff until the reauthorization deadline has passed.
In a letter to his staff, Gottlieb acknowledged that the perceived uncertainty surrounding the FDARA’s passage has been disruptive to employees on both personal and professional levels. However, he said, “because we can reasonably expect that there will be timely reauthorization of the User Fee programs by Congress by September 30, we do not anticipate initiating the process of making a determination regarding potential [reduction in force] notices unless and until September 30 passes without reauthorization.” However, he left open the possibility that the Senate might not take any action on this front, saying that, “Should Congress fail to reauthorize the User Fee programs by September 30, we will reassess our obligations at that point in time. However, my conversations with members of the Senate leave me with a high degree of confidence that the User Fee programs will be reauthorized before this September 30 deadline.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.